Chikungunya vaccine candidate update: Valneva reports further positive results
by Press Release from Outbreak News Today on (#4FMNS)
Biotech company, Valneva, announced further positive Phase 1 results for its chikungunya vaccine candidate, VLA1553 today. The objectives of VLA1553-101 Phase 1 study were to assess the overall safety and immunogenicity profile after a single vaccination across three dose levels. Todays analysis (Part B) of the ongoing study includes the overall safety and immunogenicity results ["]
The post Chikungunya vaccine candidate update: Valneva reports further positive results appeared first on Outbreak News Today.